‘Cancer and Stroke’ patient’s $2,000 drug deductible could be gone for the rest of her life

A woman who paid $2.5 million for a cancer-related drug from a New York pharmacy is suing for $100,000 in medical expenses, including the $500 per month she has been billed for the drug.

The claim filed by the New York City woman in the state Court of Claims is for medical expenses related to her illness and death.

The lawsuit says the drug is the only one that has been approved for use in the United States and that it has a high potential for causing side effects.

The drug, called nevirapine, is approved for treatment of the rare disease that causes acute myeloid leukemia.

But in 2015, the Food and Drug Administration announced that the drug could cause adverse reactions in people who had had previously had non-small cell lung cancer.

The FDA said in a statement at the time that it had not found any known safety issues related to nevirabine, and that the drugs would be removed from the market.

The New York lawsuit alleges that in 2017, the woman had a heart attack and needed to be treated at a New Jersey hospital.

She was prescribed the drug and was given two more doses in 2019 and 2020.

But the lawsuit says in January 2021, the New Jersey woman’s doctor discovered that her new dose of neviram was still being taken.

She began receiving new doses of the drug, and she died of a heart condition that doctors did not expect.

The woman, who did not give her name, said she paid for nevirampine in 2016 through her husband’s employer.

She said the couple was also paying for the treatment of her two sons who were born with the disease.

She has had no health issues, and is still paying for nevirampine.

“This is a very unusual situation, where someone would be given a drug that was approved for only the treatment, not the cure,” said Jonathan D. Pesca, an attorney for the woman.

The pharmacy she was referring to in the lawsuit is the Rite Aid Pharmacy on West 57th Street in Manhattan.

The Rite Aid website says that “in addition to the cost of the product, this drug is also FDA approved for the prevention of infections.”

Pescaras lawyer said the woman’s husband and a doctor both said the drug was not safe and that there was a higher chance that it could cause serious side effects, such as bleeding.

The two doctors said they had not seen any evidence that nevirafen was harmful.

They said that nevirefen, a different version of nevvirabines drug, has a lower potential for side effects and has been used for many years.

Pascual is a member of a New Yorkers group called The New Jersey Patient Advocacy Alliance, which supports patients with rare diseases, including people with lung cancer and certain types of cancer.

She wants the court to award medical expenses and medical expenses for funeral costs and other expenses related in part to her medical problems, and to make her eligible for unemployment compensation.

PASCAL’S LAWSUIT Pascales lawsuit claims that the FDA failed to do enough to ensure neviravine was not dangerous.

The Drug and Device Administration said that there were no known safety concerns about neviravefen.

The group has said that its lawyers have sought a jury trial.

“We are confident that this case will be successful and that all appropriate remedies will be available to vindicate our client’s dignity and deserve, as our clients have already done, compensation for the pain and suffering she suffered as a result of this cancer,” Pascals attorney, John Pascale, said in an emailed statement.

The case is Pascal v.

Rite Aid, Case No. 03-01894, New York Court of Appeals, No. 01-08958.